In this study, a total of 783 ALK rearrangement‐positive NSCLC cases were identified by DNA‐based next‐generation sequencing (NGS), including 731 patients with EML4‐ALK and 52 patients with other ALK rearrangements. The gene discussed is ALK; the disease is non-small cell lung carcinoma.